DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+3.12%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$1.35B
AUM Growth
–
Cap. Flow
+$1.35B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
44.69%
Holding
53
New
49
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
Keros Therapeutics
KROS
|
$76.1M |
| 2 |
Travere Therapeutics
TVTX
|
$76M |
| 3 |
BCYC
Bicycle Therapeutics
BCYC
|
$67M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$66.9M |
| 5 |
Jazz Pharmaceuticals
JAZZ
|
$63.7M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 99.89% |
| 2 | Real Estate | 0.11% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Keros Therapeutics
KROS
$618M
| $76.1M | 5.37% | +1,300,000 | New | +$76.1M |
|
|
2
Travere Therapeutics
TVTX
$1.56B
| $76M | 5.37% | +2,450,000 | New | +$76M |
|
|
BCYC
3
Bicycle Therapeutics
BCYC
$511M
| $67M | 4.73% | +1,100,000 | New | +$67M |
|
|
ISEE
4
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| $66.9M | 4.72% | +4,000,000 | New | +$66.9M |
|
|
5
Jazz Pharmaceuticals
JAZZ
$7.75B
| $63.7M | 4.5% | +500,000 | New | +$63.7M |
|
|
GBT
6
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $58.5M | 4.13% | +2,000,000 | New | +$58.5M |
|
7
Beam Therapeutics
BEAM
$1.66B
| $55.8M | 3.94% | +700,000 | New | +$55.8M |
|
8
Crinetics Pharmaceuticals
CRNX
$2.92B
| $54M | 3.81% | +1,900,000 | New | +$54M |
|
9
Repare Therapeutics
RPTX
$71.7M
| $44.3M | 3.13% | +2,100,000 | New | +$44.3M |
|
10
Madrigal Pharmaceuticals
MDGL
$9.76B
| $42.4M | 2.99% | +500,000 | New | +$42.4M |
|
11
4D Molecular Therapeutics
FDMT
$288M
| $41.7M | 2.94% | +1,900,000 | New | +$41.7M |
|
12
NovoCure
NVCR
$1.38B
| $41.3M | 2.92% | +550,000 | New | +$41.3M |
|
13
Immunovant
IMVT
$2.56B
| $40.7M | 2.87% | +4,775,000 | New | +$40.7M |
|
|
KDNY
14
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $39.5M | 2.79% | +2,420,502 | New | +$39.5M |
|
15
Kura Oncology
KURA
$686M
| $35.7M | 2.52% | +2,550,000 | New | +$35.7M |
|
|
DICE
16
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $33.9M | 2.4% | +1,341,004 | New | +$33.9M |
|
|
JNCE
17
DELISTED
Jounce Therapeutics, Inc. Common Stock
JNCE
| $33.4M | 2.36% | +4,000,000 | New | +$33.4M |
|
18
Esperion Therapeutics
ESPR
$448M
| $28.2M | 1.99% | +5,641,668 | New | +$28.2M |
|
19
Dyne Therapeutics
DYN
$1.92B
| $27.3M | 1.92% | +2,292,250 | New | +$27.3M |
|
20
Viridian Therapeutics
VRDN
$1.5B
| $26.4M | 1.87% | +1,336,690 | New | +$26.4M |
|
21
Fate Therapeutics
FATE
$120M
| $24.5M | 1.73% | +418,037 | New | +$24.5M |
|
22
Avidity Biosciences
RNA
$5.99B
| $23.8M | 1.68% | +1,000,000 | New | +$23.8M |
|
|
GRTS
23
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $22.8M | 1.61% | +1,771,801 | New | +$22.8M |
|
|
SLN
24
Silence Therapeutics
SLN
$227M
| $22.7M | 1.6% | +950,798 | New | +$22.7M |
|
|
TCDA
25
DELISTED
Tricida, Inc. Common Stock
TCDA
| $22.3M | 1.58% | +2,335,143 | New | +$22.3M |
|